BYTEDANCE AI DRUG SPINOFF RAISES $290M AT $1.5B

The funding round represents a significant bet on AI-driven pharmaceutical development. Anew Labs leverages machine learning to accelerate drug discovery processes, a sector gaining traction as companies seek to reduce development timelines and costs. ByteDance's move to spin off the biotech unit signals the internet giant's expansion beyond its core social media business. The company has previously invested in healthcare and AI research initiatives. HSG and IDG Capital led the investment, underscoring investor confidence in AI applications for drug development. The sector has attracted substantial capital as traditional pharma companies and startups explore computational methods to identify and validate drug candidates. Anew Labs joins a growing cohort of AI biotech firms competing to demonstrate clinical and commercial viability of algorithmic drug discovery.